More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Responsible sourcing for minerals from conflict-ridden areas is an important consideration in many industries, particularly the electronics and computer industries, but it is also an issue in the pharmaceutical and chemical industries where...

Spending on all US medicines increased only 0.6% in 2017 to $324 billion on a net basis due to greater generic volume, larger manufacturer discounts, and increasing coupon use, according to a recent analysis by the IQVIA Institute for Human Data...

A newly issued report by the European Medicines Agency details an increase in inspections at active pharmaceutical ingredient (API) facilities as part of greater cooperation between European, US, and Australian regulatory authorities and the World...

Which drugs entering the market in 2018 are poised as blockbusters? DCAT Value Chain Insights examines the contenders launching this year. A recent analysis by Clarivate Analytics points to 12 drugs entering the market this year that are expected...

The USP, a standard-setting organization, has stated that that it will not develop a new monograph for a biologic unless there is stakeholder consensus supporting its creation, including support from the FDA. In making that decision, the USP...